Hitomi Sakamoto

Hitomi Sakamoto

Auto-generated profile, based on publicly available information

Hitomi Sakamoto

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
HSHitomi Sakamoto
Hitomi Sakamoto
MAMarc Attiyeh
Marc Attiyeh
JGJeffrey M. Gerold
Jeffrey M. Gerold
AMAlvin P. Makohon-Moore
Alvin P. Makohon-Moore
AHAkimasa Hayashi
Akimasa Hayashi
CIChristine A. Iacobuzio-Donahue
Christine A. Iacobuzio-Donahue
Surgery is the only curative option for stage I/II pancreatic cancer; nonetheless, most patients will experience a recurrence after surgery and die of their disease. To identify novel opportunities for management of recurrent pancreatic cancer, we performed whole-exome or targeted sequencing of 10 resected primary cancers and matched intrapancreatic recurrences or distant metastases. We identified that recurrent disease after adjuvant or first-line platinum therapy corresponds to an increased mutational burden. Recurrent disease is enriched for genetic alterations predicted to activate MAPK/ERK and PI3K–AKT signaling and develops from a monophyletic or polyphyletic origin. Treatment-induced genetic bottlenecks lead to a modified genetic landscape and subclonal heterogeneity for driver gene alterations in part due to intermetastatic seeding. In 1 patient what was believed to be recurrent disease was an independent (second) primary tumor. These findings suggest routine post-treatment sampling may have value in the management of recurrent pancreatic cancer. Significance: The biological features or clinical vulnerabilities of recurrent pancreatic cancer after pancreaticoduodenectomy are unknown. Using whole-exome sequencing we find that recurrent disease has a distinct genomic landscape, intermetastatic genetic heterogeneity, diverse clonal origins, and higher mutational burden than found for treatment-naïve disease. See related commentary by Bednar and Pasca di Magliano, p. 762. This article is highlighted in the In This Issue feature, p. 747

8 October 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
KMKatelyn M. Mullen
Katelyn M. Mullen
JHJungeui Hong
Jungeui Hong
MAMarc Attiyeh
Marc Attiyeh
AHAkimasa Hayashi
Akimasa Hayashi
HSHitomi Sakamoto
Hitomi Sakamoto
CIChristine A. Iacobuzio-Donahue
Christine A. Iacobuzio-Donahue
The genomic features of pancreatic ductal adenocarcinoma (PDAC) have been well described, yet the evolutionary contexts within which these features occur remain unexplored. We studied genome landscapes, phylogenies, and clonal compositions of 91 PDACs in relation to clinicopathologic features. There was no difference in the number of driver mutations or evolutionary timing when each mutation occurred. High truncal density, a metric of the accumulation of somatic mutations in the lineage that gave rise to each PDAC, was significantly associated with worse overall survival. Polyclonal, monoclonal, or mixed polyclonal/monoclonal metastases were identified across the cohort, highlighting multiple forms of intertumoral heterogeneity. Advanced stage and treated PDACs had higher odds of being polyclonal, whereas oligometastatic PDACs had fewer driver alterations, a lower fractional allelic loss, and increased likelihood of being monoclonal. In sum, our findings reveal novel insights into the dynamic nature of the PDAC genome beyond established genetic paradigms. Significance: Although the pancreatic cancer genome has been described, it has not been explored with respect to stages of diagnosis or treatment bottlenecks. We now describe and quantify the genomic features of PDAC in the context of evolutionary metrics and in doing so have identified a novel prognostic biomarker.

3 April 2023
Verified
Other
Open access
HSHitomi Sakamoto
Hitomi Sakamoto
MAMarc Attiyeh
Marc Attiyeh
JGJeffrey M. Gerold
Jeffrey M. Gerold
AMAlvin P. Makohon-Moore
Alvin P. Makohon-Moore
AHAkimasa Hayashi
Akimasa Hayashi
CIChristine A. Iacobuzio-Donahue
Christine A. Iacobuzio-Donahue

3 April 2023
Verified
Other
Open access
HSHitomi Sakamoto
Hitomi Sakamoto
MAMarc Attiyeh
Marc Attiyeh
JGJeffrey M. Gerold
Jeffrey M. Gerold
AMAlvin P. Makohon-Moore
Alvin P. Makohon-Moore
AHAkimasa Hayashi
Akimasa Hayashi
CIChristine A. Iacobuzio-Donahue
Christine A. Iacobuzio-Donahue

3 April 2023
Verified
Other
Open access
HSHitomi Sakamoto
Hitomi Sakamoto
MAMarc Attiyeh
Marc Attiyeh
JGJeffrey M. Gerold
Jeffrey M. Gerold
AMAlvin P. Makohon-Moore
Alvin P. Makohon-Moore
AHAkimasa Hayashi
Akimasa Hayashi
CIChristine A. Iacobuzio-Donahue
Christine A. Iacobuzio-Donahue

3 April 2023
Verified
Other
Open access
HSHitomi Sakamoto
Hitomi Sakamoto
MAMarc Attiyeh
Marc Attiyeh
JGJeffrey M. Gerold
Jeffrey M. Gerold
AMAlvin P. Makohon-Moore
Alvin P. Makohon-Moore
AHAkimasa Hayashi
Akimasa Hayashi
CIChristine A. Iacobuzio-Donahue
Christine A. Iacobuzio-Donahue